Navigation Links
DURECT Corporation Announces First Quarter 2011 Financial Results and Update of Programs
Date:5/5/2011

h intended to deliver bupivacaine for a period of up to three days from a single application.  ELADUR demonstrated a positive efficacy trend in a Phase 2a study for post-herpetic neuralgia (PHN); a poster describing this study was presented at the 27th Annual Scientific Meeting of the American Pain Society on May 8, 2008 and is accessible on DURECT's website at www.durect.com/wt/durect/page_name/Publications.

  • TRANSDUR-Sufentanil.  We continue discussions with potential partners regarding licensing development and commercialization rights to this program to which we hold worldwide rights.

  • TRANSDUR-Sufentanil is our proprietary transdermal patch intended to deliver sufentanil to chronic pain sufferers for a period of up to seven days from a single application.

  • ORADUR-ADHD Program.  In July 2010, we and Orient Pharma commenced a Phase I clinical trial in this program evaluating multiple formulations, and in the second quarter of 2011 we and Orient Pharma anticipate commencing a second Phase I study to evaluate additional formulations.   ORADUR-ADHD applies our proprietary ORADUR technology to leading active pharmaceutical ingredients for the treatment of attention deficit disorder (ADHD).  Under an agreement with Orient Pharma, we are collaborating to perform a clinical development program through a Phase II study intended to produce a data package anticipated to support later stage development of one ADHD drug candidate and subsequent licensing by DURECT. We are responsible for formulation and study design of the pre-defined clinical program, which Orient Pharma will fund and execute.

  • Feasibility Projects and Other Activities.  During the first quarter of 2011, we continued work on several feasibility projects as a means of demonstrating that our technologies can achieve the drug delivery objectives set forth
    '/>"/>

  • SOURCE DURECT Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. DURECT Corporation Announces Fourth Quarter and Year End 2010 Financial Results
    2. DURECT Corporation Invites You to Join its Third Quarter 2010 Earnings Conference Call
    3. DURECT Corporation Announces Third Quarter 2008 Financial Results
    4. DURECTs Collaboration With Alpharma Clears HSR Review and Is Effective
    5. Techne Corporation Declares Dividend
    6. Techne Corporation Announces Acquisition
    7. SynapDx Corporation Licenses Autism Diagnostic Discoveries From Childrens Hospital Boston
    8. Vestaron Corporation Announces New Leadership
    9. Mitsubishi Chemical Corporation Signs Memorandum of Understanding for Strategic Partnership With Genomatica for Sustainable Chemicals in Asia
    10. Every Day is Earth Day for Yulex Corporation
    11. Veteran Wall Street Securities Analyst Reports on Health Discovery Corporation
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/23/2014)... July 23, 2014 a2z Inc. announces ... Mobile App, AACC Pathfinder, in its 2014 Annual ... annual meeting is planned for July 29-31, 2014 in ... to be to connect with global leaders in clinical ... and other areas of breaking science in laboratory medicine. ...
    (Date:7/22/2014)... Web) July 21, 2014 (PRWEB) July 23, 2014 ... Biomaterials, at Rutgers University. , The goal ... ideas across the full spectrum of scientists working ... research and development topics that represent the most ... been programmed to:,     Provide faculty ...
    (Date:7/22/2014)... and Technology (NIST) and California Institute of Technology ... atomic clock that is based on a chip-scale ... clock, featured on the cover of the inaugural ... is the first demonstration of all-optical control of ... frequencies to lower microwave frequencies. (Optical frequencies are ...
    (Date:7/22/2014)... , July 22, 2014   BioTE ... therapy using natural, bio-identical hormone pellets, today announced ... MD to the company.   Dr. Rouzier is joining ... physician.      Dr. Rouzier was residency ... UCLA and is a board certified emergency physician ...
    Breaking Biology Technology:AACC Enhances Attendee Experience at Its 2014 Annual Meeting & Clinical Lab Expo with a2z-Powered ChirpE Photo Booth and Mobile App 2AACC Enhances Attendee Experience at Its 2014 Annual Meeting & Clinical Lab Expo with a2z-Powered ChirpE Photo Booth and Mobile App 3The 2014 NJ Symposium on Biomaterials Science Earns Society for Biomaterials Endorsement 2'Comb on a chip' powers new NIST/Caltech atomic clock design 2Dr. Neal Rouzier Joins BioTE Medical 2Dr. Neal Rouzier Joins BioTE Medical 3
    ...  Signaling a further commitment to expand its business model in ... of the largest imaging and cardiac safety core labs ... the opening of an office in Tokyo, Japan under the ... "We are pleased to announce the creation of our new ...
    ... Wis., Jan. 16, 2012 PuraMed BioScience, Inc. (OTCBB:PMBS) ... Baacke, CPA, to the position of Chief Financial Officer. ... the Corporate Controller for PuraMed BioScience, Inc. gaining extensive ... came to PuraMed after holding a supervisory position at ...
    ... Regenesis Biomedical, Inc., a medical technology company that ... Scott Brooks has joined the company in the ... is responsible for helping scale the organization,s capabilities ... (Logo: http://photos.prnewswire.com/prnh/20120109/LA31405LOGO ) ...
    Cached Biology Technology:CoreLab Partners Opens Office in Tokyo, Japan 2PuraMed BioScience, Inc. Appoints Sue A. Baacke, CPA, as CFO 2Scott Brooks Joins Regenesis Biomedical as Chief Operating Officer 2
    (Date:7/23/2014)... the world by 2050, according to one of the ... (IPCC), may be advantageous to the physiology and the ... forage plants such as Stylosanthes capitata Vogel , ... such as Brazil., The conclusion is from a study ... at the Ribeiro Preto Faculty of Philosophy, Sciences and ...
    (Date:7/23/2014)... MA -- What do mollusks, starfish, and corals ... habitat, they are all calcifiersorganisms that use calcium ... and shells for stability and protection. , The ... published by the Marine Biological Laboratory, addresses the ... changes worldwide. , As atmospheric carbon dioxide rises, ...
    (Date:7/23/2014)... MINNETONKA, Minn. , July 23, 2014 /PRNewswire/ ... technology company specializing in clinical study management systems, ... West , a proven life sciences industry executive ... named Chief Operating Officer (COO).  Clareece will be ... and sales growth, operational efficiency and quality product/service ...
    Breaking Biology News(10 mins):An increase in temperature by 2050 may be advantageous to the growth of forage plants 2An increase in temperature by 2050 may be advantageous to the growth of forage plants 3An increase in temperature by 2050 may be advantageous to the growth of forage plants 4Calcification in changing oceans explored in special issue of The Biological Bulletin 2MedNet Appoints Clareece West As Chief Operating Officer 2
    ... Nanoparticles will soon be used as tiny shuttles to ... a more targeted way than was possible in the ... the nanoparticles in medicine, concerns have arisen about their ... nanoparticles and their toxicity rely on the ability of ...
    ... Mass. April 28, 2011 A project to use ... $100,000 grant from The Bill & Melinda Gates Foundation today. ... of the Harvard School of Engineering and Applied Sciences (SEAS) ... aim is to develop a Microbial Fuel Cell-based charger that ...
    ... One of the most critical tasks that a dividing ... set of genetic information to each new daughter cell. Now, ... issue of the journal Cell , provides fascinating new ... segregation of human chromosomes during cell division. During ...
    Cached Biology News: Inverting a standard experiment sometimes produces different results 2 Inverting a standard experiment sometimes produces different results 3Harvard's engineering school receives $100,000 Grand Challenges Explorations grant 2Harvard's engineering school receives $100,000 Grand Challenges Explorations grant 3New insight into chromosome segregation: Centromere-independent kinetochore assembly 2
    Compound(s) tested through a broad panel of 38 ligand binding and enzyme assays targeting the Central Nervous System. Used to determine selectivity and potential CV/Renal liabilities of compounds....
    ... Human serum is obtained from normal human ... by a test for Human Immunodeficiency Virus ... Virus (Anti-HIV 1/2), Hepatitis C Virus (HCV), ... (HbsAg) and Non-reactive by a screening test ...
    Compound(s) screened through any number of client selected assays. Client also selects number of concentrations and replicates....
    Values of steady state parameters for enzyme activities are determined....
    Biology Products: